èšæ¶åºŠ
15å
35å
0å
0å
0å
ã¢ã«ãŠã³ãç»é²ããŠãè§£ççµæãä¿åããã
åé¡äžèЧ
1
è èã®æ§é ãšæ©èœã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠããã®ã¯ã©ããã1 ã€éžã¹ã
ã¢ã«ãã¹ããã³ã¯å¯è ç®è³ªãã«ã¢ã³ãããœãã¬ã·ã³ã¯äžåäœåèãã«ã¢ã³ã®äžçš®ã§ããã
2
å©å°¿è¬ã®é©å¿çŸæ£ãšããŠèª€ã£ãŠãããã®ãäžã€éžã¹
ç³å°¿ç
3
以äžã®ãã¡æ£ãããã®ãäžã€éžã¹
æå€§ Na å©å°¿ãé«ãã»ã©å©å°¿å¹æã¯é«ãã
4
浞éå§æ§å©å°¿è¬ã«ã€ããŠèª€ã£ãŠããèšè¿°ãäžã€éžã¹
è³å§ãäžæããã
5
çŒæ¿æ°Žã®ç£çæå¶ã«ããçŒå§ãäžããçé žè±æ°Žé µçŽ é»å®³è¬ãšããŠèª€ã£ãŠãããã®ã 1 ã€éžã¹
ããã«ã«ãã³
6
ãã¢ãžãç³»å©å°¿è¬ã«ã€ããŠèª€ã£ãŠãããã®ã 1 ã€éžã¹ã
ãã¢ãžãç³»å©å°¿è¬ã¯ç®¡è å ã®ãããªãŠã ã€ãªã³æ¿åºŠãäžããã
7
ã«ãŒãå©å°¿è¬ã«ã€ããŠèª€ã£ãŠããèšè¿°ãäžã€éžã¹
ã«ãŒãå©å°¿è¬ã®äžã§ãããã»ããïŒã©ã·ãã¯ã¹)ã®äœçšæéã¯æãé·ãã
8
ã«ãªãŠã ä¿ææ§å©å°¿è¬ã«ã€ããŠèª€ã£ãŠããèšè¿°ãäžã€éžã¹
å¯è é«è³ªãã«ã¢ã³ã§ããã¢ã«ãã¹ããã³ã®åããæå¶ãã
9
ããœãã¬ã·ã³åå®¹äœæ®æè¬ããã³å¿æ¿æ§ãããªãŠã å©å°¿ãããã補å€ã«ã€ããŠèª€ã£ãŠããèšè¿°ãäžã€éžã¹ã
ããœãã¬ã·ã³åå®¹äœæ®æè¬ã¯éåç®¡ã®æ°Žééæ§ãäžæãããæ°Žã®ååžåãä¿é²ããããšã§å©å°¿äœçšã瀺ãã
10
å©å°¿è¬ã®å¯äœçšããã³çŠå¿ã«ã€ããŠèª€ã£ãŠããèšè¿°ãäžã€éžã¹
ã«ãªãŠã ä¿ææ§å©å°¿è¬ã®ãã¡ãããªã¢ã ãã¬ã³ã¯ã女æ§åä¹³æ¿ãåŒãèµ·ããããšãããã
11
å©å°¿è¬ã®å€é·ãšå±æã«ã€ããŠèª€ã£ãŠããèšè¿°ã 1 ã€éžã¹ã
ARNI ã¯ãããªãŠã å©å°¿ãããããåè§£ããã¢ã³ã®ãªãã³ã·ã³â ¡ã®åæ³ãä¿é²ããã
12
ã¢ã¬ã«ã®ãŒã®åé¡ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ãããïŒã€éžã¹ã
ã¢ã¬ã«ã®ãŒã®åã®ãã¡ãæã¢ã¬ã«ã®ãŒè¬ã®å¯Ÿè±¡ãšãªãã®ã¯â ¡åã§ããã
13
è¥æºçްèããéé¢ããã±ãã«ã«ã¡ãã£ãšãŒã¿ãŒã®ãã¡ãè±é¡ç²ã«ããç©è³ªãäžã€éžã¹ã
ãã¹ã¿ãã³
14
ãã¹ã¿ãã³ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠããã®ã¯ã©ããã1ã€éžã¹ã
å¥œé žçã®éèµ°ãçŽæ¥çã«èªå°ããã®ã¯ H1å容äœã§ããã
15
æ¬¡ã®æã¢ã¬ã«ã®ãŒè¬ã®ãã¡ããã¹ã现èã«çŽæ¥äœçšãããã®ã¯ã©ããã1 ã€éžã¹ã
ã±ãã«ã«ã¡ãã£ãšãŒã¿ãŒé颿å¶è¬
16
ã¢ã¬ã«ã®ãŒçŸæ£ã§çšããããæãã¹ã¿ãã³è¬ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ãããïŒã€éžã¹ã
第äºäžä»£ H1 åå®¹äœæ®æè¬ã¯ãè¡æ¶²è³é¢éãééãããããäžæ¢æå¶äœçšãããã
17
次ã®äžã§ããã€ã³ããªãšã³ã®äžã§ããåŒ·ãæ°ç®¡æ¯å¹³æ»çåçž®äœçšããã¡ãã·ã¹ãã€ãã«ãã€ã³ããªãšã³ãšç·ç§°ããã矀ã«å«ãŸããªããã®ãçããã
ãã€ã³ããªãšã³B4
18
Th2 ãµã€ãã«ã€ã³é»å®³è¬ãæ IgE æäœã«ã€ããŠèª€ã£ãŠãããã®ã¯ã©ããã1 ã€éžã¹ã
æ IgE æäœã¯ãã¹ã现èäžã® IgE å容äœãšçµåããã
19
ç³è³ªã³ã«ãã³ã€ãã®ã¯ããããšããŠæ£ãããã®ã¯ã©ãããäžã€éžã¹ã
ãã¹ããªããŒãŒ A2 ã®ç£çãããã¯æŽ»æ§ãæå¶ãã
20
ç³è³ªã³ã«ãã³ã€ãé¢é£ ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ãããïŒã€éžã¹ã
åžå ¥ã¹ããã€ãã®äž»ãªé©å¿çŸæ£ã¯ã¢ã¬ã«ã®ãŒæ§éŒ»çã§ãã
21
æžæäœçæ³(ç¹ç°çå ç«çæ³)ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠããã®ã¯ã©ãããïŒã€éžã¹ã
æžæäœçæ³ã§ã¯ã¢ã¬ã«ã²ã³ãæäžããããšã§ãIgE æäœãå¢ãããIgG æäœãæžããããšãç®æšãšããŠããã
22
æ¥æ¬ã«ãããã¢ã¬ã«ã®ãŒçŸæ£ã®æ²»çã«ã€ããŠãæ£ãããã®ã以äžã®éžæè¢ãã 1 ã€éžã¹
çŸç¶ãã¢ã¬ã«ã®ãŒçŸæ£æ²»çã®äžå¿ãšãªã£ãŠããã®ã¯è¬ç©çæ³ã§ããã
23
ã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã®æ§é ã«ã€ããŠèª€ã£ãŠãããã®ãäžã€éžã¹ã
DNA ãŠã€ã«ã¹ã§ããšã³ãããŒããæã€ã
24
以äžã®éžæè¢ããééã£ãŠãããã®ãéžã¹ã
ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã¯ä¿éºé©çšã§ããã
25
以äžã®ãã¡ããééã£ãŠãããã®ãéžã¹ã
è±æ®»é»å®³å€ã®é©å¿ã¯ AãB åäž¡æ¹ã§ããã
26
ãã€ã©ããããŒãŒé»å®³å€ã®äžã§ 10 æ³ä»¥äžã®æªæå¹Žãžã®äœ¿çšãååå·®ãæ§ããããŠãããã®ã¯ã©ããã
ãªã»ã«ã¿ããã«
27
ãšã³ããã¯ã¬ã¢ãŒãŒé»å®³å€ã§ããããããµãã«ã«ã€ããŠééã£ãŠããã®ã¯ã©ããã
ã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã® tRNA ãé»å®³ããããšã«ãããæãŠã€ã«ã¹å¹æãçºæ®ããã
28
æã€ã³ãã«ãšã³ã¶è¬ã®ãã¡ããã©ãã«ã«ã€ããŠééã£ãŠããã®ã¯ã©ããã
ã¡ãã«åãšãªã³é žåã«ãã£ãп޻æ§äœã«ãªãã
29
ãã«ãã¹ãŠã€ã«ã¹ã®ç¹åŸŽã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ããã1 ã€éžã¹ã
RNAã²ãã ãæã€ã
30
åçŽãã«ãã¹ãŠã€ã«ã¹(HSV)ã«ã€ããŠãæ£ããæç« ãïŒã€éžã¹
åçŽãã«ãã¹è³çã®æ²»çã¯èšºæç¢ºå®åã«è¡ãããããšãããã
31
垯ç¶ç±ç¹åŸç¥çµç(PHN)ã®æ²»çã«äœ¿ãè¬ã¯ã©ãããïŒã€éžã¹ã
ãã¬ã¬ããªã³
32
CMV èºçã«ã€ããŠã誀ã£ãŠãããã®ã¯ã©ãããã²ãšã€éžã¹ã
æ¯åææã«ãã£ãŠèå ã«çããçŸæ£ã§ããã
33
æãã«ãã¹ãŠã€ã«ã¹è¬ã«é¢ãã以äžã®èšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ããã1ã€éžã¹ã
ã¢ã·ã¯ããã«ã®æŽ»æ§äœã¯ dATP ãšæ®æããŠDNAããªã¡ã©ãŒãŒãé»å®³ããã
34
代衚çãªãµã€ãã¡ã¬ããŠã€ã«ã¹è¬ã§ããã¬ã³ã·ã¯ããã«ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ãããïŒã€éžã¹ã
DNA ã¿ãŒãããŒãŒè€åäœãé»å®³ããããšã§ããŠã€ã«ã¹ç²åã®åœ¢æãæå¶ããã
35
æ¢è¡æ©æ§ã«é¢ããèšè¿°ã®ãã¡ãäºæ¬¡è¡æ 圢æã«åœãŠã¯ãŸããã®ã 1 ã€éžã¹ã
ãã£ããªã³ãèµ€è¡çãå·»ã蟌ãã§è¡æ ã圢æãã
36
è¡æ çã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã 1 ã€éžã¹ã
éèè¡æ çã¯éèã§å¡æ ãèµ·ããçŸæ£ã§ããã
37
以äžã®èšè¿°ã®ãã¡ããŠã£ã«ãã§ãŠã®äžåŸŽã«åœãŠã¯ãŸããªããã®ã 1 ã€éžã¹ã
è¡ç®¡ã®æ¡åŒµ
38
æç𮿧è¡ç®¡å ååºçå矀ïŒDisseminated intravascular coagulation, DICïŒã«é¢ããèšè¿°ã®ãã¡ãæ£ãããã®ã 1 ã€éžã¹ã
DIC ã®äºå€§çç¶ãšã¯ãè¡æ æ§èåšçç¶ãšåºè¡çç¶ã®ããšã§ããã
39
æè¡å°æ¿è¬ã«é¢ããèšè¿°ã®ãã¡ãæ£ãããã®ã 1 ã€éžã¹ã
ADP å容äœé»å®³è¬ã¯ãP2Y12 ãé»å®³ããè¡å°æ¿æŽ»æ§ãæå¶ããã
40
以äžã®ãã¡ãéã¹ããã€ãæ§æççè¬ïŒNon-Steroidal Anti-Inflammatory Drugs, NSAIDsïŒé»å®³ããé µçŽ ã 1 ã€éžã¹ã
Cyclooxygenase (COX)
41
æè¡å°æ¿è¬ã«é¢ããèšè¿°ã®ãã¡ãæ£ãããã®ã 1 ã€éžã¹ã
ã¢ã¹ããªã³ãžã¬ã³ããšã¯ã¢ã¹ããªã³æäžéãå¢éããéã«è¡å°æ¿åéæå¶å¹æãæžåŒ±ããŠããŸãããšã§ããã
42
ãã¹ããžãšã¹ãã©ãŒãŒ (Phosphodiesterase, PDE) é»å®³è¬ã«é¢ããèšè¿°ã®ãã¡ãæ£ãããã®ã 1 ã€éžã¹ã
ã·ãã¹ã¿ãŸãŒã«ã¯ PDEâ ¢é»å®³è¬ã§ãããcAMP ã®åè§£ãæå¶ããPKA ãæŽ»æ§åãããCaã€ãªã³æ¿åºŠãäžããããšã§äœçšããè¡ç®¡æ¡åŒµè¬ã§ããã
43
æè¡å°æ¿è¬ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã 1 ã€éžã¹ã
ãã«ã°ã¬ãã«ã¯ä»£è¬ã«ããæŽ»æ§åãå¿ èŠãšãå人差ãå°ãªãã æè¡åã®äŒè¬æéãé·ãã
44
æååºè¬ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ãïŒã€éžã¹ã
PTã¯æ¥è§Šå åæŽ»æ§ç©è³ªããAPTTã¯çµç¹ããã³ããã©ã¹ãã³ãå ããŠæ€æ»ããã
45
以äžã®ãã¡ãåŠå©Šãžã®æäžãçŠå¿ãšãªã£ãŠããæååºè¬ã 1 ã€éžã¹ã
ã¯ã«ãã¡ãªã³
46
è¡æ 溶解è¬ã«ã€ããŠã®èª¬æã®ãã¡æ£ãããã®ã 1 ã€éžã¹ã
çŸåš u-PA ã¯èšåºã§ããŸã䜿ãããŠããªãã
47
以äžã®èšè¿°ã®äžã§èª€ã£ãŠãããã®ãäžã€éžã¹ã
è²§è¡ãšã¯è¡äžãã¢ã°ããã³æ¿åºŠãäœäžããç æ°ã§ããã
48
è²§è¡ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ãããäžã€éžã¹ã
è æ§è²§è¡ã¯å°çæ§äœè²çŽ æ§è²§è¡ã§ããã
49
è²§è¡ã®æ²»çã«ã€ããŠãæ£ãããã®ã¯ã©ãããäžã€éžã¹ã
茞è¡ã®éã«ã¯ãéãã¬ãŒãå€ãçšããŠé€éãè¡ãå Žåãããã
50
è æ§è²§è¡ã®èšºæã«ã€ããŠèª€ã£ãŠãããã®ã¯ã©ããïŒäžã€éžã¹ã
è é害ãæã€äººãéäžè¶³ã®ã¿ãåå ãšããè²§è¡ãåããå Žåãè æ§è²§è¡ãšèšããã
51
è æ§è²§è¡ã«é¢ãã以äžã®èšè¿°ã®ãã¡ãæ£ãããã®ã¯ã©ãããäžã€éžã¹ã
æ²»çè¬ã®äœ¿çšã§ãé床ã«è²§è¡ãæ¹åããããšã«ããåŒãèµ·ããããå¯äœçšãããã
52
è æ§è²§è¡ã«ã€ããŠæ£ããèšè¿°ã 1 ã€éžã¹
HIF ã¯é žçŽ æ¿åºŠäŸåç㪠EPO ã®ç£çã«å¯äžããŠãããé žçŽ æ¿åºŠæ£åžžç¶æ ã§ã¯ PHD ãšããæ°Žé žåé µçŽ ãæŽ»æ§åãããŠãããHIFα ãµããŠããããæ°Žé žåããŠããã®åŸãŠãããã³åãåããŠãããã¢ãœãŒã ã§åè§£ãããã
53
å€§çæ§è²§è¡ã®æ²»çè¬ã«ã€ããŠæ£ãã説æãããŠãããã®ãäžã€éžã¹ã
ãã©ãªã¢ãã³ã®æåã§ããèé žã¯ãŠã©ã·ã«ããããã³çãåæããéã®è£é µçŽ ã§ããã
54
å€§çæ§è²§è¡ã«ã€ããŠã®èª¬æã®ãã¡ã誀ã£ãŠãããã®ãäžã€éžã¹ã
å€§çæ§è²§è¡ã¯æ 逿§è²§è¡ã®äžã§ãæãå€ãèŠãããè²§è¡ã§ããã
55
ãã¿ãã³ B12 ãšè²§è¡ã®é¢ä¿ã«ãããŠæ£ããéžæè¢ã¯ã©ããïŒäžã€éžã¹ïŒ
ãããªã©ã«ããèã®å šææè¡ã¯ïŒè²§è¡ã®åå ãšãªãããïŒ
56
äœå ã®éã®åæ ã«ã€ããŠééã£ãŠãã説æã¯ã©ãããäžã€éžã¹ã
éã¯äœå ã§åæããããããé£äºããã®æåã¯äžèŠã§ããã
57
以äžã®çç¶ã§ã次ã®ãã¡éæ¬ ä¹è²§è¡ã«ç¹åŸŽçã§ãªããã®ã¯ã©ãããäžã€éžã¹ã
çŒçŒçµèèŒçœ
58
鿬 乿§è²§è¡ã®æ²»çã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠããã®ã¯ã©ããã1 ã€éžã¹ã
çµå£æ²»çã¯ããã¢ã°ããã³å€ãæ£åžžã«ãªã£ãæç¹ã§çµäºããã
59
èé žåæ³æ©æ§ãšèç²èé²åŸ¡æ©æ§ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ãããäžã€éžã¹ã
å£çްèãæã€èãããã³ãã³ã㯠HïŒãèå è åŽã«åæ³ããNaïŒã现èå ã«åã蟌ãã
60
éã¹ããã€ãæ§æççè¬ïŒNSAIDsïŒã«ããæ¶åæ§æœ°çã«é¢ããèšè¿°ã®ãã¡ãæ£ãããã®ã¯ã©ãããïŒã€éžã¹ã
ððºðž2ã®äœçšã¯ãèé žåæ³æå¶ããç²æ¶²åæ³ä¿é²ã»èè¡æµå¢å ãªã©ã®èç²èä¿è·äœçšã§ããã
61
ãããªèææã«ããæ¶åæ§æœ°çã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ããã1 ã€éžã¹ã
ãããªèææã§ã¯ãD 现èããã®ãœããã¹ã¿ãã³åæ³ãé»å®³ããããããG 现èããã®ã¬ã¹ããªã³åæ³ãæå¶ãããã
62
æ¶åæ§æœ°çæ²»çè¬ã®åé¡ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ãããäžã€éžã¹ã
æ¶åæ§æœ°çã®ãªã¹ã¯ãã¡ã¯ã¿ãŒã®äœæžã«ã¯ãã«ãã§ã€ã³ã®æåããçŠç ãç¯é ããããªèã®é€èãªã©ãæå¹ã§ããã
63
ãããã³ãã³ãé»å®³è¬(PPI)ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠããã®ã¯ã©ããã1 ã€éžã¹ã
åŸæ¥å PPI ã¯ãããã³ãã³ãã®é µçŽ æŽ»æ§ãå¯éçã«é»å®³ããã
64
H2 å容äœåã³ H2 åå®¹äœæ®æè¬ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠããã®ã¯ã©ãããïŒã€éžã¹ã
H2 åå®¹äœæ®æè¬ã¯ HïŒåå®¹äœæ®æè¬ãšåæ§ã®ãã¹ã¿ãã³ã®äœçšãæããã
65
æã³ãªã³è¬ãæã¬ã¹ããªã³è¬ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ãããäžã€éžã¹ã
ééžæçæã ã¹ã«ãªã³è¬ã¯å¯äœçšãå°ãªãã®ã§çŸåšã§ããã䜿çšãããŠãã
66
ããã¹ã¿ã°ã©ã³ãžã³è£œå€ã«é¢ããæ¬¡ã®èšè¿°ã®ãã¡ã誀ã£ãŠããã®ã¯ã©ãããïŒã€éžã¹ã
ããã¹ã¿ã°ã©ã³ãžã³è£œå€ã®ä»£è¡šäŸã§ããããœããã¹ããŒã«ã¯ãPGE2 èªå°äœè£œå€ã§ãããåŠåš ãŸãã¯ãã®çãã®ãã女æ§ã«ã¯äœ¿çšçŠå¿ã§ããã
67
H.pylori ã®é€èçæ³ã«é¢ããæ¬¡ã®èšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ãããïŒã€éžã¹
äžæ¬¡é€èãè¡ãããã®åŸã®åæ€æ»ã§ãéœæ§ã ã£ãå Žåãäºæ¬¡é€èãè¡ãããããèæ§èã®åºçŸã«ãããè¿å¹Žã¯äºæ¬¡é€è段éã§ã®é€èæåç㯠50%ã»ã©ã«çãŸã£ãŠããã
68
æ¶åæ§æœ°çæ²»çè¬ã®æ¯èŒã䜿ãããã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ãããäžã€éžã¹ã
H2 åå®¹äœæ®æè¬ã«ã¯ä¿éºé©çšäžåŠæ¹æéãããã
69
éæµæ§é£éçã«é¢ããèšè¿°ã®ãã¡ãæ£ãããã®ã¯ã©ãããïŒã€éžã¹ã
å¶é žè¬ã¯é屿åãå«ãå Žåããããããè çŸæ£ãæã€æ£è ã®å Žåã¯ãå¯äœçšã«æ³šæãå¿ èŠã§ããã
70
次ã®è¬å€ã®ãã¡ãæ¥æ¬ã«ãããŠãã£ãšãæ°ããæ¿èªãããã®ã¯ã©ããã
ãªã¡ãã©ãŸãŒã«ïŒãããã³ãã³ãé»å®³è¬ïŒ
71
骚圢æãšéªšåžåã«ã€ããŠã誀ã£ãŠãããã®ãéžã¹ã
骚åžåã¯ãè¡äžãã骚ã«Ca ãåžåããè¡äžã® Caæ¿åºŠãäžããäœçšãããã
72
骚ç²é¬çã®èšºæã«ã€ããŠã誀ã£ãŠãããã®ãéžã¹ã
è匱æ§éªšæãããã°ã骚å¯åºŠã«ããã骚ç²é¬çãšèšºæãããã
73
骚ç²é¬çã®äºé²æ³ã«ã€ããŠãæ£ãããã®ãäžã€éžã¹ã
ãžã§ã®ã³ã°ãªã©ã®ç©ççè² è·ã倧ããéåã¯éªšç²é¬çäºé²ã«å¹æçãšãããŠãã
74
ãã¿ãã³D3 補å€ã«ã€ããŠãæ£ãããã®ã 1ã€éžã¹ã
PTH åæ³ãæå¶ãããšãç ŽéªšçŽ°èã®æ©èœã¯äœäžããã
75
å¯ç²ç¶è ºãã«ã¢ã³ãš PTH 補å€ããªãã©ããã«ã€ããŠãæ£ãããã®ãäžã€éžã¹ã
å¯ç²ç¶è ºãã«ã¢ã³(PTH)ã¯éªšåžåãä¿é²ããäœçšãããã
76
ããã¹ããã«ã€ããŠééã£ãŠãããã®ãäžã€éžã¹ã
ããã¹ããã®æçšæã«ã¯äœ Ca äºé²ãšããŠãã¿ãã³ C ãšã«ã«ã·ãŠã 補å€ãçµå£è£å ãããããšãããã
77
ã¹ã¯ã¬ãã¹ãã³ãšæã¹ã¯ã¬ãã¹ãã³æäœè¬ïŒãã¢ãœãºããïŒã«ã€ããŠãæ£ãããã®ãäžã€éžã¹ã
ãã¢ãœãºããã¯ç Žéªšçްèã®ååãæå¶ããã®ã§éªšåžåæå¶äœçšãããã
78
骚ç²é¬çæ²»çè¬ãšããŠäœ¿ããã SERM åã³ãšã¹ããã²ã³ã«ã€ããŠééã£ãŠãããã®ã 1ã€éžã¹ã
ãšã¹ããã²ã³è£œå€ã¯ãåå®®ãä¹³è ºã®ãšã¹ããã²ã³å容äœã«å¯ŸããŠã¢ã³ã¿ãŽãã¹ããšããŠåãã
79
ãã¹ãã¹ãããŒãç³»è¬ã«ã€ããŠèª€ã£ãŠãããã®ãéžã¹ã
ãã¹ãã¹ãããŒãç³»è¬ãæåããããåŸã«é£äºãããŠãããã
80
骚ç²é¬çæ²»çè¬ã«ã«ã·ããã³ã®äœçšã«ã€ããŠééã£ãŠãããã®ãïŒã€éžã¹ã
ã«ã«ã·ããã³ã®äž»ãªæšçåšå®ã¯éªšãšèèã§ããã
81
ãã¿ãã³K2 ã«ã€ããŠééã£ãŠãããã®ã1ã€éžã¹
γ-ã«ã«ãããã·ã°ã«ã¿ãã³é žæ®åºãã°ã«ã¿ãã³é žæ®åºã«å€åããããšã Glaåãšããã
82
æ²»çè¬ã®éžæã«ã€ããŠæ£ãããã®ãéžã¹
骚ç²é¬çã®éç床ãé«ãå Žåãæ RANKLæäœè¬ãPTH補å€ãæã¹ã¯ã¬ãã¹ãã³æäœè¬ã䜿ãããšãèŠéã«å ¥ãã
83
次ã®ãã¡èª€ã£ãŠããèšè¿°ã¯ã©ãã
ããã¯å°¿é žãå°¿çŽ ã«ä»£è¬ããŠææ³ãã
84
ããªã³å¡©åºã®ä»£è¬ãææ³ã«é¢ããèšè¿°ã«ã€ããŠã誀ã£ãŠããã®ã¯ã©ããã1 ã€éžã¹ã
å°¿é žã¯é äœå°¿çŽ°ç®¡ã§ååžåãšåæ³ãç¹°ãè¿ãã
85
URAT1ïŒå°¿é žãã©ã³ã¹ããŒã¿ãŒïŒã«é¢ããèšè¿°ã®ãã¡ãæ£ãããã®ã¯ã©ããã1 ã€éžã¹ã
åå®ã«æåããã®ã¯åå€å±å€§åŠå»åŠéšè «çç çåŠææã®æŠæ¬ç¯€å çã§ããã
86
é«å°¿é žè¡çã®åé¡ã«é¢ããèšè¿°ã®ãã¡ãæ£ãããã®ã¯ã©ãããïŒã€éžã¹ã
å°¿é žææ³äœäžåã§ã¯ãå°¿é žã¯ãªã¢ã©ã³ã¹ã¯äœäžããã
87
å°¿é žåæé»å®³è¬ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã¯ã©ããã1 ã€éžã¹ã
ã¢ãããªããŒã«ã¯ããµã³ãã³ãªãã·ããŒãŒã®ã¿ãéžæçã«é»å®³ããã
88
次ã®ïŒã€ã®èšè¿°ã®ãã¡æ£ãããã®ãäžã€éžã¹
ãããã©ã㯠URATïŒãžã®éžææ§ããã³ãºããããã³ããé«ãããã³ãºããããã³ããå¿ èŠéãå°ãªãã
89
çé¢šã®æ²»çè¬ã«ã¯ãïŒïŒïŒç颚çºäœã«å¯Ÿããè¬ïŒïŒïŒè¡æž å°¿é žå€ãæ¯æ£ããè¬ ããããããã®æäžã®é çªã«ã€ããŠæ£ãããã®ãéžã¹ã
ïŒïŒïŒâ¡ïŒïŒïŒ
90
ç ç³æ²»çã®äžã§ä»¥äžã®éžæè¢ã®äžããæã身äœãžã®è² æ ãå°ãããã®ãéžã¹ã
ESWL
91
次ã®ãã¡ãä»£è¬æ®æè¬ã§ãªããã®ãïŒã€éžã¹ã
ã¯ãããžã³
92
å°¿é žåè§£é µçŽ è¬ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠããã®ã¯ã©ããã1 ã€éžã¹ã
ããã®äœå ã«ååšããå°¿é žãªãã·ããŒãŒã«ããå°¿é žã®åè§£ãä¿é²ããã
93
èé žæ¬ ä¹çã«é¢ããèšè¿°ã®ãã¡èª€ã£ãŠããã®ã¯ã©ããã
èé žãäžè¶³ãããšèµ€è¡çã¯éåžžããå°ãããæ°ãå°ãªããªãããè²§è¡ãèµ·ããã
94
èªç¥çã®çœ¹æ£çã§æãå€ããã®ã¯ã©ããã
ã¢ã«ããã€ããŒåèªç¥ç
95
æ¹èšé·è°·å·åŒç¥èœè©äŸ¡ã¹ã±ãŒã«ïŒHDSãŒR)ã«ãããæãéèŠãªåœ¹å²ã¯äœãïŒ
èªç¥æ©èœã®äœäžãæ©æçºèŠããé©åãªå°éå»ãžã®ç޹ä»ãè¡ãããš
96
ã¢ã«ããã€ããŒå èªç¥çã®è³ç å€ã«ã€ããŠãæ£ãããã®ã 1 ã€éžã¹ã
çºçåæã® MRI æèŠã¯ã»ãšãã©æ£åžžã§ããã
97
ã¢ã«ããã€ããŒåèªç¥çã«ããããã³ãªã³ä»®èª¬ããã³ã°ã«ã¿ãã³é žç¥çµæ¯ä»®èª¬ã«ã€ããŠè¿°ã¹ãæ¬¡ã®æç« ã®ãã¡ã誀ã£ãŠãããã®ã 1 ã€éžã¹ã
ã³ãªã³ä»®èª¬ã«åºã¥ããŠãã¢ã»ãã«ã³ãªã³åæé µçŽ ãé»å®³ããè¬ãéçºãããŠããã
98
ã¢ã«ããã€ããŒåèªç¥çã«ããããAβ 仮説ã«é¢ããèšè¿°ã®ãã¡ãæ£ãããã®ã 1 ã€éžã¹ã
α ã»ã¯ã¬ã¿ãŒãŒã®æŽ»æ§åã¯ã¢ã«ããã€ããŒç ã®æ²»çã«ãããŠã广ãæåŸ ãããã
99
ã¢ã«ããã€ããŒåèªç¥çã®ç æ ã«ã€ããŠãæ£ãããã®ã 1 ã€éžã¹ã
ã¿ãŠã¯åŸ®å°ç®¡çµåã¿ã³ãã¯è³ªã§ãããæ£åžžãªç¥çµçްèã®æ©èœã«éèŠã§ããã
100
ã¢ã«ããã€ããŒåèªç¥çãããã«å¯Ÿããã¢ã»ãã«ã³ãªã³ãšã¹ãã©ãŒãŒïŒAChEïŒé»å®³è¬ã«é¢ããèšè¿°ã®ãã¡ã誀ã£ãŠãããã®ã 1 ã€éžã¹ã
ã¢ã«ããã€ããŒåèªç¥çã§ã¯ ACh å容äœã«å¯Ÿããèªå·±æäœãã§ãããããã¢ã»ãã«ã³ãªã³ã«ããç¥çµäŒéã劚ãããã